Evaxion releases transcript of Q2 2026 business update and financial results call
Reuters2026/08/21 10:58- Evaxion discussed its Q2 2026 business update and financial results on Aug. 20, led by CEO Helen Tayton-Martin, CSO/COO Birgitte Rono, CFO Thomas Schmidt.
- Management set an October ESMO presentation for three-year Phase 2 EVX-01 melanoma data, including standalone vaccine and anti-PD-1 combination outcomes.
- Earlier EVX-01 readouts cited 75% overall response rate, 25% complete responses, 92% still in response; 86% vaccine targets triggered tumor-specific responses.
- Introduced preclinical EVX-05 glioblastoma off-the-shelf vaccine with Duke; target discovery completed, 16 ERV fragments selected from about 1.5 million.
- Cash was USD 14 million at quarter-end; net loss USD 3.7 million; runway reiterated into H2 2027, supported by an ATM facility.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Trump Energy Chief Says Fuel Export Ban Wouldn't Lower Prices
Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk
Costco Wholesale Nearly Doubles Kirkland Motor Oil Price, Caps Purchases at Two Weekly
Liquidity Unconcerned? The Federal Reserve Hits 'Pause' Again, Ceasing Reserve Management Bond Purchases Until Mid-October
The Federal Reserve announced on Monday that it will not conduct short-term Treasury bond purchases for reserve management purposes in the next phase for the second consecutive month, indicating that policymakers are satisfied with the level of bank reserves in the financial system.
Crypto prices
More
